Clinical trials: Dose-Finding Study
Sinusitis, Acute
Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis
The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal spray (FFNS), without the use of an antibiotic, in the treatment of adult and adolescent subjects who are 12 years of age and older with…
- Trial name
- NCT01018030
- Testing
- FFNS 110 mcg QD, FFNS 110 mcg BID
- Where
- 87 sites in Bulgaria, Canada and 10 more
- Volunteers
- 741 people
- Sponsor
- GlaxoSmithKline
HER2 + Breast Cancer
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
This is a multicenter, open-label, dose-finding trial using a backfill Bayesian optimal interval (BF-BOIN) design to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for paclitaxel oral solution…
- Trial name
- GBCF002 (NCT07739511)
- Testing
- Paclitaxel oral solution plus Trastuzumab and Pertuzumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liu Shu
Obesity
Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity
XW003 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05111912
- Testing
- XW003, Saxenda
- Where
- Australia
- Volunteers
- 206 people
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Beta Thalassemia Major Anemia, Myelodysplastic Syndrome
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
The goal of this clinical trial is to learn about SP-420 ability to remove iron from organs in subjects with transfusion-dependent β-thalassemia or transfusion-dependent low-risk myelodysplastic syndrome.
- Trial name
- NCT05693909
- Testing
- SP-420
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Pharmacosmos A/S
Edema Secondary, Edema Leg
A Dose-finding Study of JMKX003142 in Treatment of Renal Edema
To evaluate the safety,efficacy, and pharmacokinetic characteristics of JMKX003142 administered randomly, double-blind, placebo-controlled study in Chinese renal edema patients with inadequate response to conventional diuretic…
- Trial name
- NCT06670534
- Testing
- JMKX003142 tablets
- Where
- 2 sites in China
- Volunteers
- 133 people
- Sponsor
- Jemincare
Migraine
A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
The purpose of this study is to determine a recommended dose of topiramate in participants with migraine (type of severe headache that occurs periodically and is often associated with nausea, vomiting, and constipation or…
- Trial name
- NCT01081795
- Testing
- Topiramate
- Where
- 29 sites in Japan
- Volunteers
- 387 people
- Sponsor
- Janssen Pharmaceutical K.K.
Solid Tumor, Metastatic Bladder Cancer
Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies
The purpose of this study is to determine the maximum tolerated dose of RX-3117 in subjects with advanced or metastatic solid tumors (Phase 1).
- Trial name
- NCT02030067
- Testing
- RX-3117
- Where
- 12 sites in United States
- Volunteers
- 127 people
- Sponsor
- Processa Pharmaceuticals
Peripheral T-Cell Lymphoma (PTCL)
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral…
- Trial name
- NCT02594267
- Testing
- Pralatrexate Injection
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Acrotech Biopharma Inc.
mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with darolutamide in subjects with mCRPC.
- Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease
- Trial name
- NCT06190899
- Testing
- Gedatolisib, Darolutamide
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 54 people
- Sponsor
- Celcuity Inc
COVID-19
Dose-finding Study for AdimrSC-2f Vaccine
AdimrSC-2f is a subunit protein-based vaccine produced using the baculovirus insect cells manufacturing process to prevent Coronavirus disease 2019 (COVID-19).
- Trial name
- NCT05104489
- Testing
- AdimrSC-2f
- Where
- Indonesia
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Klebsiella Pneumoniae Infection, Vaccine
An Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of a Bivalent Klebsiella Pneumoniae Vaccine (CHO-V08) in Healthy Adults
CHO-V08 is currently being developed as a prevention vaccine against nosocomial and community-acquired infection caused by hypervirulent Klebsiella pneumoniae K1 and K2 serotypes.
- Trial name
- NCT07016152
- Testing
- Glyconjugate Klebsiella pneumoniae bivalent vaccine
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Cho Pharma Inc.
Acute Myeloid Leukemia
Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission
Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine.
- Trial name
- PrE0901 (NCT01656252)
- Testing
- Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- PrECOG, LLC.
Cancer, Solid Tumor
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
This study will evaluate safety, pharmacodynamics and biomarkers of subcutaneous (SC) DK210(EGFR) given as monotherapy and in combination with immunotherapy, chemotherapy or radiation.
- Conditions
- Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05704985
- Testing
- DK210 (EGFR), Radiation therapy, Immune checkpoint blockers
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- DEKA Biosciences
Carotid Artery Disease
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease
The purpose of this study is to find the optimal dose from 3 different dose levels - 0.15 mL, 0.5 mL and 1.5 mL of Optison in assessing the presence of disease of the carotid arteries when comparing pre-contrast to post-contrast…
- Trial name
- NCT01394926
- Testing
- Optison
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- GE Healthcare
Arthritis, Rheumatoid
A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects
This study is to evaluate the efficacy and safety of ASP015K monotherapy and to evaluate the dose-dependent response of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects given ASP015K for 12 weeks.
- Trial name
- NCT01649999
- Testing
- peficitinib
- Where
- 7 sites in Japan
- Volunteers
- 281 people
- Sponsor
- Astellas Pharma Inc
Heart Failure, Worsening Heart Failure (WHF)
To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
This Study Aims to Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)
- Trial name
- NCT06264310
- Testing
- R2R01
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- River 2 Renal Corp.
Peripheral T-cell Lymphoma
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
- Trial name
- NCT01839097
- Testing
- Belinostat, CHOP
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Suppression of Ovulation
Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone
This clinical trial investigates a new vaginal delivery system made of silicone rubber, containing Nestorone®, a 19-nor progesterone derivative and a low dose of serum estradiol (E2).
- Trial name
- NCT02626208
- Testing
- Nestorone®/Estradiol Contraceptive Vaginal Ring
- Where
- 7 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Premier Research
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
American Ginseng in Treating Patients With Cancer-Related Fatigue
RATIONALE: American ginseng may help relieve cancer-related fatigue. PURPOSE: This clinical trial is studying how well American ginseng works in treating patients with cancer-related fatigue.
- Trial name
- NCT00182780
- Testing
- American ginseng
- Volunteers
- 290 people
- Sponsor
- Alliance for Clinical Trials in Oncology